EMMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EMMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Emmaus Life Sciences's other long-term liabilities for the quarter that ended in Sep. 2024 was $13.68 Mil.
Emmaus Life Sciences's quarterly other long-term liabilities declined from Mar. 2024 ($16.97 Mil) to Jun. 2024 ($15.37 Mil) and declined from Jun. 2024 ($15.37 Mil) to Sep. 2024 ($13.68 Mil).
Emmaus Life Sciences's annual other long-term liabilities declined from Dec. 2021 ($23.17 Mil) to Dec. 2022 ($21.71 Mil) and declined from Dec. 2022 ($21.71 Mil) to Dec. 2023 ($17.36 Mil).
The historical data trend for Emmaus Life Sciences's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Long-Term Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
Emmaus Life Sciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Long-Term Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
Thank you for viewing the detailed overview of Emmaus Life Sciences's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Seah H. Lim | director | 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503 |
Willis C Lee | director, officer: Vice Chairman & COO | 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501 |
Yutaka Niihara | director, 10 percent owner, officer: Chairman and CEO | 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501 |
Lori Teranishi | director | 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813 |
Charles William Stark | officer: SVP, Clinical Development | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503 |
George Sekulich | officer: CIO & SVP | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503 |
Lui Alfred Fu Kong | director | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503 |
Jane Pine Wood | director | 956 MAIN STREET, DENNIS MA 02638 |
Wei Peu Zen | director | 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503 |
Sherwood Joseph Charles Iii | officer: Chief Financial Officer | 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503 |
Masaharu Osato | director | 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505 |
Ian Harvey Zwicker | director | 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503 |
Lan T. Tran | officer: Chief Administrative Officer | 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501 |
Robert Iv Dickey | director | 320 WEST MERMAID LANE, PHILADELPHIA PA 19118 |
Yasushi Nagasaki | officer: Sr. VP Finance | 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501 |
From GuruFocus
By PRNewswire PRNewswire • 06-22-2022
By PRNewswire PRNewswire • 11-17-2022
By PRNewswire PRNewswire • 05-15-2023
By GuruFocus Research • 02-13-2024
By PRNewswire PRNewswire • 05-23-2022
By PRNewswire • 07-23-2024
By PRNewswire • 08-14-2023
By PRNewswire PRNewswire • 03-31-2023
By PRNewswire • 09-10-2024
By PRNewswire • 04-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.